№ 4 / 2014 / 18-24

Phenotypic and functional features of human M2-like macrophages

Author: Sakhno L.V.¹, Tikhonova M.A.², Shevela E.Ya.³, Tyrinova T.V.⁴, Leplina O.Yu.⁵, Ostanin A.A.⁶, Chernykh E.R.⁷

Abstract

The phenotypic and functional properties of macrophages generated from blood monocytes of healthy donors (n = 22) in the presence of GM-CSF using standard conditions (M1-cells) and in conditions of deficiency of serum/growth factors (M2-cells) were investigated. It has been shown that in contrast to the M1-cells, the population of M2-like macrophages was characterized by lower stimulatory activity in allo-MLC and enhanced content of CD206+cells, and cells, expressing of the co-inhibitor (B7-H1) and pro-apoptotic molecules (FasL, TRAIL). Multiplex proteomic analysis of 17 cytokines showed that M2-cells were notable for lower production of immunoregulatory and proinflammatory cytokines/chemokines (IFN-γ, IL-5, IL-6, TNF-α, IL-17, MCP-1). At the same time, the level of immunosuppressive cytokines was either not changed (IL-10), or also reduced (IL-13). Overexpression of B7-H1, CD200R, CD206 and TRAIL on M2-cells was correlated with a lower secretion of IFN-γ, IL-2, IL-5, IL-13, IL-1β, TNF-α, IL-17, MCP-1, MIP-1β. Therefore, the deficiency of the immunoregulatory and inflammatory cytokines is one of the possible mechanisms of low stimulatory activity of M2 macrophages in allo-MLC. Low ability of M2-cells to activate of T-lymphocytes in allo-MLC can also be associated with their direct cytotoxic and/or cytostatic action through FasL/TRAIL– or B7-H1-mediated signaling pathways, respectively.

Key words

macrophages, phenotype, functional dichotomy, cytokines

References

1. Cassetta L., Cassol E., Poli G. Macrophage polarization in health and disease // SciWorld J. 2011. 11. 2391–2402.

2. Chernykh E.R., Kafanova M.Yu., Shevela E.Ya. et al. Autologous M2-like macrophage applications in children with cerebral palsy // Cell. Therapy Transpl. 2011. 3. (10). 1–9.

3. Chernykh E.R., Shevela E.Ya., Sakhno L.V. et al. The generation and properties of human M2-like macrophages: potential candidates for CNS repair? // Cell. Therapy Transpl. 2010. 2. (6). 1–7.

4. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury // Exp. Neurol. 2008. 209. 378–388.

5. Fadok V.A., Bratton D.L., Konowal A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF // J. Clin. Invest. 1998. 101. 890–898.

6. Gabrilolovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumors // Nat. Rev. Immunol. 2012. 12. (4). 253–268.

7. Gordon S. Alternative activation of macrophages // Nat. Rev. Immunol. 2002. 3. 23–35.

8. Hohlfeld R., Kerschensteiner M., Meinl E. Dual role of inflammation in CNS disease // Neurology. 2007. 68. (Suppl. 3). 58–63.

9. Kigerl K.A., Gensel J.C., Ankeny D.P., et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord // J. Neurosci. 2009. 29. 13435–13444.

10. Knoller N., Auerbach G., Fulga V. et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results // J. Neurosurg. 2005. 3. 173–181.

11. Koning N., van Eijk M., Pouwels W. et al. Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation // J. Innate Immunol. 2010. 2. 195–200.

12. Manrique S.Z., Correa M.A.D., Hoelzinger D.B. et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth // J. Exp. Med. 2011. 208. (7). 1485–1499.

13. Mantovani A., Biswas S.K., Galdiero M.R. et al. Macrophage plasticity and polarization in tissue repair and remodeling // J. Pathol. 2013. 229. 176–185.

14. Martinez F.O., Sica A., Mantovani A. et al. Macrophage activation and polarization // Front. Biosci. 2008. 13. (2). 453–461.

15. Nagamatsu T., Schust D.J. The contribution of macrophages to normal and pathological pregnancies // Am. J. Reprod. Immunol. 2010. 63. (6). 460–471.

16. Rapalino O., Lazarov-Spiegler O., Agranov E. et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats // Nat. Med. 1998. 4. 814–821.

17. Schwartz M., Yoles E. Immune-based therapy for spinal cord repair: autologous macrophages and beyond // J. Neurotrauma. 2006. 23. 360–370.

18. Shechter R., London A., Varol C. et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice // PLoS. 2009. 6. 1–16.

19. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development // J. Clin. Invest. 2007. 117. (5). 1155–1166.

20. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas // J. Clin. Invest. 2012. 122. (3). 787–795.

21. Vega M.A., Corbi A.L. Human macrophage activation: too many functions and phenotypes for a single cell type // Immunologia. 2006. 25. (4). 248–272.

22. Verreck F.A.W., de Boer T., Langenberg D.M.L. et al. Phenotypic and functional profiling of human proinflammatory type-1 and antiinflammatory type-2 macrophages in response to microbial antigens and IFN– γ– and CD40L-mediated costimulation // J. Leukoc. Biol. 2006. 79. 285–293.

23. Verreck F.A.W., de Boer T., Langenberg D.M.L. et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria // Proc. Natl. Acad. Sci. USA. 2004. 101. (3). 4560–4565.

24. Walker P.A., Shah S.K., Harting M.T., Cox C.S. Adult progenitor cell therapies for traumatic brain injury: barriers and opportunities in translation // Dis. Model. Mech. 2009. 2. (1–2). 23–38.

25. Yin Y., Cui Q., Li Y. et al. Macrophage-derived factors stimulate optic nerve regeneration // J. Neurosci. 2003. 23. 2284–2293.

About Authors (Correspondence):

Sakhno L.V. – candidate of biological sciences, senior researcher of laboratory of cellular immunotherapy, e-mail: ct_lab@mail.ru

Tikhonova M.A. – candidate of biological sciences, senior researcher of laboratory of cellular immunotherapy, e-mail: ct_lab@mail.ru

Shevela E.Ya. – doctor of medical sciences, leading researcher of laboratory of cellular immunotherapy, e-mail: ct_lab@mail.ru

Tyrinova T.V. – candidate of biological sciences, researcher of laboratory of cellular immunotherapy, e-mail: ct_lab@mail.ru

Leplina O.Yu. – doctor of medical sciences, leading researcher of laboratory of cellular immunotherapy, e-mail: ct_lab@mail.ru

Ostanin A.A. – doctor of medical sciences, professor, head of clinical department, e-mail: ct_lab@mail.ru

Chernykh E.R. – doctor of medical sciences, professor, corresponding member of RAMS, head of laboratory of cellular immunotherapy, e-mail: ct_lab@mail.ru

Full Text

3-4-2014.pdf

Received: 09/02/2015